Breaking News

Sanofi’s Sarclisa Gains EU Approval for Multiple Myeloma

Approval is based on GMMG-HD7 phase 3 study for those who are transplant-eligible, newly diagnosed with multiple myeloma.

By: Rachel Klemovitch

Assistant Editor

The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. This follows the positive opinion of the European Medicines Agency’s Committee for Medicinal Products for Human Use on June 19, 2025.  The approval is based on results from part one of the two-part, double-r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters